BMO Capital Reiterates Outperform Rating on Arvinas Inc. (ARVN) Following Q3 2022 Earnings

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $95.00 price target on Arvinas Inc. (NASDAQ: ARVN).

The analyst comments "This morning, ARVN reported its 3Q financial and pipeline updates. The Phase 2 VERITAC trial of ARV-471, ARVN's lead program will be presented at SABCS this December, and we'll be looking for potential differentiation and benefit in late-line ER+ breast cancer patients. ARVN initiated a Phase 2 trial with ARV-766 in metastatic castration-resistant prostate cancer (mCRPC) and Phase 1 data for ARV-766 will now be disclosed in 2Q23 at a medical meeting, based on our communication with management post-3Q release. We maintain Outperform rating and target price."

For an analyst ratings summary and ratings history on Arvinas Inc. click here. For more ratings news on Arvinas Inc. click here.

Shares of Arvinas Inc. closed at $42.47 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• New Street Research Upgrades Micron Technology (MU) to Buy